The Addition of Carfilzomib to a Lenalidomide-Based Triplet Improves Outcomes in Newly Diagnosed Transplant Eligible Myeloma Patients with Renal Impairment: A Subgroup Analysis of the Myeloma XI Trial

Pawlyn, C., Menzies, T. orcid.org/0000-0003-3896-7228, Davies, F.E. et al. (12 more authors) (2020) The Addition of Carfilzomib to a Lenalidomide-Based Triplet Improves Outcomes in Newly Diagnosed Transplant Eligible Myeloma Patients with Renal Impairment: A Subgroup Analysis of the Myeloma XI Trial. In: Blood. 62nd ASH Annual Meeting and Exposition, 05-08 Dec 2020, Virtual. American Society of Hematology , pp. 40-43.

Metadata

Item Type:	Proceedings Paper
Authors/Creators:	Pawlyn, C. Menzies, T. https://orcid.org/0000-0003-3896-7228 Davies, F.E. Rana, R. Pinney, J. Cook, G. https://orcid.org/0000-0001-7196-7364 Gregory, W.M. Jenner, M.W. Jones, J.R. Kaiser, M.F. Owen, R.G. Morgan, G. Jackson, G.H. Cairns, D. https://orcid.org/0000-0002-2338-0179 Drayson, M.T.
Dates:	Published: 5 November 2020 Published (online): 3 August 2021
Institution:	The University of Leeds
Academic Units:	The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Inst of Clinical Trials Research (LICTR) (Leeds)
Funding Information:	Funder Grant number Cancer Research UK Supplier No: 138573 A25447
Depositing User:	Symplectic Publications
Date Deposited:	05 Nov 2024 11:49
Last Modified:	05 Nov 2024 11:49
Status:	Published
Publisher:	American Society of Hematology
Identification Number:	10.1182/blood-2020-139238
Related URLs:	Author
Open Archives Initiative ID (OAI ID):	oai:eprints.whiterose.ac.uk:219145

CORE (COnnecting REpositories)

The Addition of Carfilzomib to a Lenalidomide-Based Triplet Improves Outcomes in Newly Diagnosed Transplant Eligible Myeloma Patients with Renal Impairment: A Subgroup Analysis of the Myeloma XI Trial

Metadata

Download not available

Export

Statistics